Coherus Biosciences (CHRS) PT Lowered to $8 at Barclays
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.17 --0%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 18
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 18
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Coherus Biosciences (NASDAQ: CHRS) to $8.00 (from $13.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Costco Wholesale (COST) PT Raised to $1,040 at DA Davidson Following Q4 Earnings
- LTIMindtree Ltd (LTIM:IN) PT Lowered to INR3,620 at Citi
- Wipro Ltd. (WPRO:IN) (WIT) PT Lowered to INR140 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
